Subscribe To

Price Alert Latest News Economic Calendar News

RVPH / Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CUPERTINO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held September 12–14, 2022 and invites investors to participate via virtual one-on-one meetings or in-person in New York, NY. Please see additional details below: Read More

Demo Live Account See Partner Details

Content Topics

Reviva

Pharmaceuticals

Present

Wainwright

24th

Annual

Global

Investment

Conference

Stock

RVPH

Posted: Sep 7 2022, 08:02

Author Name: GlobeNewsWire

RVPH News

By Seeking Alpha
November 2, 2023

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo o

By Reuters
October 30, 2023

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study.

By Seeking Alpha
September 27, 2023

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, with results expected in October 2023. A previous

By GlobeNewsWire
March 7, 2023

Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clin

By GlobeNewsWire
September 7, 2022

Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CUPERTINO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clin

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.